NCR(+)ILC3 concentrate in human lung cancer and associate with intratumoral lymphoid structures.
Paolo CarregaFabrizio LoiaconoEmma Di CarloAngelo ScaramucciaMarco MoraRomana ConteRoberto BenelliGrazia Maria SpaggiariClaudia CantoniStefania CampanaIrene BonaccorsiBarbara MorandiMauro TruiniMaria Cristina MingariLorenzo MorettaGuido FerlazzoPublished in: Nature communications (2015)
Tertiary lymphoid structures (TLSs) are a common finding in non-small cell lung cancer (NSCLC) and are predictors of favourable clinical outcome. Here we show that NCR(+) innate lymphoid cell (ILC)-3 are present in the lymphoid infiltrate of human NSCLC and are mainly localized at the edge of tumour-associated TLSs. This intra-tumoral lymphocyte subset is endowed with lymphoid tissue-inducing properties and, on activation, produces IL-22, TNF-α, IL-8 and IL-2, and activates endothelial cells. Tumour NCR(+)ILC3 may interact with both lung tumour cells and tumour-associated fibroblasts, resulting in the release of cytokines primarily on engagement of the NKp44-activating receptor. In patients, NCR(+)ILC3 are present in significantly higher amounts in stage I/II NSCLC than in more advanced tumour stages and their presence correlate with the density of intratumoral TLSs. Our results indicate that NCR(+)ILC3 accumulate in human NSCLC tissue and might contribute to the formation of protective tumour-associated TLSs.
Keyphrases
- endothelial cells
- small cell lung cancer
- nk cells
- advanced non small cell lung cancer
- induced pluripotent stem cells
- end stage renal disease
- high glucose
- signaling pathway
- ejection fraction
- pluripotent stem cells
- high resolution
- induced apoptosis
- chronic kidney disease
- stem cells
- vascular endothelial growth factor
- mass spectrometry
- peritoneal dialysis
- epidermal growth factor receptor